Integrity Bio, LakePharma become Curia

By The Science Advisory Board staff writers

February 15, 2022 -- Curia (formerly AMRI) announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.

The change reflects the accelerated integration of the acquired companies into Curia. Curia completed the acquisition of Integrity Bio in August 2021 and closed the LakePharma transaction in September 2021. Integrity Bio and Lake Pharma's legal entity names will begin transitioning immediately.

Curia is a contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers.

Curia unveils mRNA solution
Curia, a contract research, development, and manufacturing organization, unveiled its mRNA solution. The new offering includes discovery, process development,...
Curia finalizes LakePharma acquisition
Curia has finalized its acquisition of LakePharma, a privately held biologics drug discovery, clinical research, and manufacturing organization.
Curia to expand manufacturing capacity
Curia plans to expand its commercial manufacturing capacity at its facility in Rensselaer, NY, and is investing more than $35 million in the expanded...
Curia to acquire LakePharma
Curia, formerly known as Albany Molecular Research, has inked a deal to acquire private biologics firm LakePharma.
Curia to acquire Integrity Bio
Curia, formerly known as Albany Molecular Research, has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter